Olaparib is an FDA-approved PARP inhibitor that is widely used in ovarian cancer (Dizon, 2017), prostate cancer (Rebello et al., 2021), and pancreatic cancer (Park et al., 2021) treatment. Here, PARP1 is linked to ovarian carcinoma.